Literature DB >> 25210539

Novel approaches in the high-risk prostate cancer patient: Summary of key research presented at AUA 2014.

.   

Abstract

Another topic of focus at AUA 2014 was the subgroup of prostate cancer patients deemed to be at high risk.

Entities:  

Year:  2014        PMID： 25210539      PMCID： PMC4145692          DOI： 10.5489/cuaj.2285

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  5 in total

1.  Hormonal treatment before radical prostatectomy: a 3-year followup.

Authors:  G Aus; P A Abrahamsson; G Ahlgren; J Hugosson; S Lundberg; M Schain; S Schelin; K Pedersen
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

2.  Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.

Authors:  Mark S Soloway; Kapil Pareek; Rooholiah Sharifi; Zev Wajsman; David McLeod; David P Wood; Antonio Puras-Baez
Journal:  J Urol       Date:  2002-01       Impact factor: 7.450

3.  CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.

Authors:  L H Klotz; S L Goldenberg; M Jewett; J Barkin; M Chetner; Y Fradet; J Chin; S Laplante
Journal:  Urology       Date:  1999-04       Impact factor: 2.649

4.  4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.

Authors:  C C Schulman; F M Debruyne; G Forster; F P Selvaggi; A R Zlotta; W P Witjes
Journal:  Eur Urol       Date:  2000-12       Impact factor: 20.096

5.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

Authors:  Mack Roach; Kyounghwa Bae; Joycelyn Speight; Harvey B Wolkov; Phillip Rubin; R Jeffrey Lee; Colleen Lawton; Richard Valicenti; David Grignon; Miljenko V Pilepich
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.